Loomis, Sayles & Company’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.8M | Buy |
4,662
+160
| +4% | +$59.3K | ﹤0.01% | 493 |
|
|
2026
Q1 | $1.32M | Sell |
4,502
-5,000
| -53% | -$1.64M | ﹤0.01% | 484 |
|
|
2025
Q4 | $3.33M | Sell |
9,502
-15,141
| -61% | -$5.12M | ﹤0.01% | 435 |
|
|
2025
Q3 | $7.96M | Sell |
24,643
-1,681
| -6% | -$523K | 0.01% | 388 |
|
|
2025
Q2 | $10.2M | Buy |
26,324
+4,636
| +21% | +$1.86M | 0.01% | 378 |
|
|
2025
Q1 | $9.43M | Sell |
21,688
-76,690
| -78% | -$30.8M | 0.01% | 363 |
|
|
2024
Q4 | $36.3M | Buy |
98,378
+39,893
| +68% | +$16.7M | 0.05% | 161 |
|
|
2024
Q3 | $30.4M | Buy |
58,485
+4,844
| +9% | +$2.59M | 0.04% | 196 |
|
|
2024
Q2 | $29.1M | Sell |
53,641
-3,330
| -6% | -$1.76M | 0.04% | 194 |
|
|
2024
Q1 | $29.5M | Buy |
56,971
+39,362
| +224% | +$19.6M | 0.04% | 204 |
|
|
2023
Q4 | $8.3M | Buy |
17,609
+8,798
| +100% | +$4.07M | 0.01% | 354 |
|
|
2023
Q3 | $3.84M | Sell |
8,811
-494
| -5% | -$224K | 0.01% | 408 |
|
|
2023
Q2 | $4.13M | Buy |
9,305
+480
| +5% | +$221K | 0.01% | 406 |
|
|
2023
Q1 | $4.06M | Buy |
8,825
+312
| +4% | +$148K | 0.01% | 410 |
|
|
2022
Q4 | $4.37M | Sell |
8,513
-107
| -1% | -$54.3K | 0.01% | 381 |
|
|
2022
Q3 | $3.92M | Sell |
8,620
-21,799
| -72% | -$10.4M | 0.01% | 378 |
|
|
2022
Q2 | $14.7M | Sell |
30,419
-17,631
| -37% | -$8.72M | 0.03% | 300 |
|
|
2022
Q1 | $23.6M | Sell |
48,050
-39,084
| -45% | -$17.9M | 0.03% | 266 |
|
|
2021
Q4 | $40.4M | Sell |
87,134
-33,512
| -28% | -$14.1M | 0.05% | 198 |
|
|
2021
Q3 | $45M | Buy |
120,646
+7,275
| +6% | +$2.76M | 0.06% | 172 |
|
|
2021
Q2 | $43.3M | Sell |
113,371
-18,844
| -14% | -$7.2M | 0.05% | 187 |
|
|
2021
Q1 | $47.5M | Buy |
132,215
+95,628
| +261% | +$30.8M | 0.06% | 148 |
|
|
2020
Q4 | $11.7M | Buy |
36,587
+32,736
| +850% | +$10M | 0.02% | 339 |
|
|
2020
Q3 | $1.03M | Sell |
3,851
-93
| -2% | -$25K | ﹤0.01% | 443 |
|
|
2020
Q2 | $1.04M | Buy |
3,944
+1,413
| +56% | +$377K | ﹤0.01% | 453 |
|
|
2020
Q1 | $574K | Buy |
2,531
+2,108
| +498% | +$574K | ﹤0.01% | 489 |
|
|
2019
Q4 | $128K | Buy |
423
+39
| +10% | +$10.7K | ﹤0.01% | 555 |
|
|
2019
Q3 | $92K | Buy |
+384
| New | +$105K | ﹤0.01% | 558 |
|
|
2019
Q2 | – | Sell |
-9,042
| Closed | -$2.59M | – | 622 |
|
|
2019
Q1 | $2.59M | Buy |
+9,042
| New | +$2.62M | 0.01% | 484 |
|
|
2018
Q1 | – | Sell |
-127
| Closed | -$29K | – | 885 |
|
|
2017
Q4 | $29K | Buy |
+127
| New | +$27K | ﹤0.01% | 705 |
|
|
2017
Q2 | – | Sell |
-53
| Closed | -$9K | – | 962 |
|
|
2017
Q1 | $9K | Buy |
+53
| New | +$8.43K | ﹤0.01% | 814 |
|
|
2016
Q2 | – | Sell |
-42
| Closed | -$6K | – | 1039 |
|
|
2016
Q1 | $6K | Sell |
42
-34
| -45% | -$4.54K | ﹤0.01% | 915 |
|
|
2015
Q4 | $11K | Hold |
76
| – | – | ﹤0.01% | 849 |
|
|
2015
Q3 | $11K | Hold |
76
| – | – | ﹤0.01% | 897 |
|
|
2015
Q2 | $12K | Buy |
+76
| New | +$12.1K | ﹤0.01% | 794 |
|
Other funds holding ELV
Loomis, Sayles & Company's ELV Position: Q2 2026 in Review
Loomis, Sayles & Company increased its Elevance Health (ELV) stake by 3.6% in Q2 2026, buying an estimated $59.3K and bringing the position to 4,662 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #493.
Loomis, Sayles & Company first reported a position in ELV in Q2 2015 and has held it in 35 quarters since. The position peaked at $47.5M in Q1 2021. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- Loomis, Sayles & Company held 4,662 shares of Elevance Health worth $1.8M as of Q2 2026.
- Loomis, Sayles & Company bought 160 Elevance Health shares in Q2 2026, an estimated $59.3K.
- Elevance Health made up ﹤0.01% of Loomis, Sayles & Company's portfolio in Q2 2026, its #493 holding.
- Loomis, Sayles & Company first reported a position in Elevance Health in Q2 2015 and has held it in 35 quarters since.
- Loomis, Sayles & Company's Elevance Health position peaked at $47.5M in Q1 2021.
- 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.